iqwigsmall

IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition

pharmafile | April 11, 2016 | News story | Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV 

German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally lower benefit in comparison with the competition, according to an early benefit assessment.

The regulator has said the drug offered minor added benefit for pre-treated women, but not for men.

The drug is indicated if the previous treatment has failed or cannot be continued due to side effects.

Advertisement

The Federal Joint Committee (G-BA) said between four groups of patients depending on age (adolescents/ adults) and previous treatment (pre-treated/ treatment-naive). Genvoya was compared with efavirenz in combination with two other drugs in treatment-naive patients, and with individual antiretroviral therapy in pre-treated patients.

US drug major Bristol-Myers Squibb (NYSE: BMY) markets efavirenz  under the brand name Sustiva in the US, the United Kingdom, Ireland, France, Germany, Italy, and Spain. 

Anjali Shukla

Related Content

Gilead’s HIV treatment meets primary trial endpoint

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia

Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

European Commission approves HIV prevention injection

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …

The Gateway to Local Adoption Series

Latest content